Patents by Inventor Marina Bacac

Marina Bacac has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20210355234
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: July 28, 2021
    Publication date: November 18, 2021
    Inventors: Christian KLEIN, Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Sylvia HERTER, Joaquin ARRIBAS, Rocio VICARIO
  • Bispecific T cell activating antigen binding molecules
    Patent number: 11117965
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: September 14, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20210253704
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 19, 2021
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20210253703
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 19, 2021
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • TREATMENT METHOD
    Publication number: 20210252144
    Abstract: The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.
    Type: Application
    Filed: April 26, 2021
    Publication date: August 19, 2021
    Inventors: Marina BACAC, Stefan EVERS, Christian KLEIN, Pavel PISA, Eva ROSSMANN, Jose SARO, Pablo UMANA
  • Treatment method
    Patent number: 11013801
    Abstract: The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: May 25, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Stefan Evers, Christian Klein, Pavel Pisa, Eva Rossmann, Jose Saro, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20210101996
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: December 10, 2020
    Publication date: April 8, 2021
    Inventors: Christian KLEIN, Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Sylvia HERTER, Joaquin ARRIBAS, Rocio VICARIO
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20210101979
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 8, 2021
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA
    Publication number: 20210070873
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 11, 2021
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20210070882
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: May 18, 2020
    Publication date: March 11, 2021
    Inventors: Marina BACAC, Christian KLEIN, Wolfgang SCHAEFER, Stefan KLOSTERMANN, Sabine IMHOF-JUNG, Michael MOLHOJ, Joerg Thomas REGULA, Pablo UMANA, Sylvia HERTER, Christiane NEUMANN
  • Bispecific T cell activating antigen binding molecules
    Patent number: 10882918
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: January 5, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Marina Bacac, Anne Freimoser-Grundschober, Sylvia Herter, Joaquin Arribas, Rocio Vicario
  • Combination therapy with targeted OX40 agonists
    Publication number: 20200392237
    Abstract: The present invention relates to combination therapies employing tumor targeted bispecific OX40 antibodies, in particular anti-FAP/anti-OX40 antibodies in combination with T-cell activating anti-CD3 bispecific antibodies specific for a tumor-associated antigen, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: April 28, 2020
    Publication date: December 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Sandra GRAU-RICHARDS, Christian KLEIN, Johannes SAM, Pablo UMANA, Sabine LANG, Maria AMANN, Mudita PINCHA
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20200385470
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 10, 2020
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20200376119
    Abstract: The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
    Type: Application
    Filed: February 11, 2020
    Publication date: December 3, 2020
    Inventors: Marina BACAC, Sara COLOMBETTI, Christian KLEIN, Johannes SAM, Jose SARO, Pablo UMANA
  • Method for the selection of antibodies against BCMA
    Patent number: 10851171
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: December 1, 2020
    Assignee: ENGMAB SARL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20200347147
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: July 23, 2020
    Publication date: November 5, 2020
    Inventors: Marina BACAC, Tanja FAUTI, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Ekkehard MOESSNER, Michael MOLHOJ, Christiane NEUMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS
    Publication number: 20200325225
    Abstract: The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: March 20, 2020
    Publication date: October 15, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Sabine LANG, Viktor LEVITSKI, Pablo UMAÑA
  • COMBINATION THERAPY OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS
    Publication number: 20200325238
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: March 16, 2020
    Publication date: October 15, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Claudia FERRARA KOLLER, Christian KLEIN, Mario PERRO, Johannes SAM, Pablo UMAÑA, Wei XU
  • COMBINATION THERAPY OF TUMOR TARGETED ICOS AGONISTS WITH T-CELL BISPECIFIC MOLECULES
    Publication number: 20200306373
    Abstract: The present invention relates to agonistic ICOS-binding molecules comprising at least one antigen binding domain that binds to a tumor-associated antigen and their use in combination with T-cell bispecific molecules in the treatment of cancer, the agonistic ICOS-binding molecules as such, pharmaceutical compositions comprising these molecules, and methods of using the same.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Tanja FAUTI, Christian KLEIN, Johannes SAM, Pablo UMANA, Ramona MURR, Joerg ZIELONKA, Lucas HABEGGER
  • Bispecific T cell activating antigen binding molecules
    Patent number: 10781258
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: September 22, 2020
    Assignee: Roche Glycart AG
    Inventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl